Celularity Inc. (NASDAQ:CELU) Short Interest Update

Celularity Inc. (NASDAQ:CELU) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 415,800 shares, an increase of 7.1% from the March 15th total of 388,300 shares. Approximately 3.9% of the company’s stock are sold short. Based on an average daily trading volume, of 253,600 shares, the days-to-cover ratio is currently 1.6 days.

Hedge Funds Weigh In On Celularity

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. American International Group Inc. acquired a new stake in shares of Celularity in the 2nd quarter valued at about $25,000. Ergoteles LLC acquired a new position in shares of Celularity during the second quarter worth about $25,000. JPMorgan Chase & Co. bought a new position in shares of Celularity during the second quarter worth about $28,000. Legal & General Group Plc bought a new position in shares of Celularity during the second quarter worth about $29,000. Finally, Renaissance Technologies LLC acquired a new stake in Celularity in the 4th quarter valued at approximately $31,000. 19.02% of the stock is owned by institutional investors and hedge funds.

Celularity Trading Down 5.4 %

Celularity stock opened at $3.31 on Thursday. The company has a 50 day moving average of $4.79 and a 200-day moving average of $3.27. Celularity has a twelve month low of $1.59 and a twelve month high of $8.90.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.